Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Antibody-maytansinoid conjugates designed to bypass multidrug resistance.

Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, Lai KC, Widdison WC, Kellogg B, Johnson H, Pinkas J, Lutz RJ, Singh R, Goldmacher VS, Chari RV.

Cancer Res. 2010 Mar 15;70(6):2528-37. doi: 10.1158/0008-5472.CAN-09-3546. Epub 2010 Mar 2.

2.

Targeted cancer therapy: conferring specificity to cytotoxic drugs.

Chari RV.

Acc Chem Res. 2008 Jan;41(1):98-107. Epub 2007 Aug 18. Review.

PMID:
17705444
3.

ADME of antibody-maytansinoid conjugates.

Erickson HK, Lambert JM.

AAPS J. 2012 Dec;14(4):799-805. doi: 10.1208/s12248-012-9386-x. Epub 2012 Aug 9. Review.

4.

Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.

Janthur WD, Cantoni N, Mamot C.

Int J Mol Sci. 2012 Nov 28;13(12):16020-45. doi: 10.3390/ijms131216020. Review.

5.

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.

Chu YW, Polson A.

Future Oncol. 2013 Mar;9(3):355-68. doi: 10.2217/fon.12.189. Review.

PMID:
23469971
6.

Antibody-maytansinoid conjugates for the treatment of myeloma.

Lutz RJ, Whiteman KR.

MAbs. 2009 Nov-Dec;1(6):548-51. Epub 2009 Nov 9. Review.

7.

Mechanisms of Resistance to Antibody-Drug Conjugates.

Loganzo F, Sung M, Gerber HP.

Mol Cancer Ther. 2016 Dec;15(12):2825-2834. Epub 2016 Oct 25. Review.

PMID:
27780876

Supplemental Content

Support Center